膦甲酸钠治疗慢性乙型肝炎重度患者的临床观察

目的 观察膦甲酸钠治疗慢性乙型肝炎重度患者的疗效及副作用。方法 选择HBV DNA阳性的慢性乙型肝炎重度患者44例，随机分为治疗组和对照组。两组均给予基础治疗，治疗组另加用膦甲酸钠治疗28天。以后两组均继续给予综合基础保肝治疗至病情缓解。停用膦甲酸钠后随访6个月。结果 用药28天时，治疗组患者血清HBV DNA水平下降程度优于对照组（P〈0．05）；治疗组和对照组患者临床症状均明显缓解，血生化指标明显好转，但两组比较差异无显著性意义（P〉0．05）。随访6月时，两组患者HBVDNA下降≥2 log的例数分别为9／21（42．9％）和6／20（30．0％，x^2=0．731，P〉0．05）。无严重副反应发生。结论 短期静脉滴注膦甲酸钠用于治疗HBV DNA阳性的慢性乙型肝炎重度患者，能快速抑制乙型肝炎病毒的复制。

The therapeutic efficacy of foscarnet sodium in the treatrnent of patients with chronic hepatitis B of severe type

Objective To investigate the therapeutic efficacy of fosearuet sodium in the treatment of patients with chronic hepatitis B of severe type. Methods Forty four patients were randomly divided into foscarnet sodium treatment and conventional groups. Each group consisted of 22 patients and the two groups were both treated by basic surperting therapy. At the same time,the treatment group were treated with fosearnet sodium at 3.0g twice daily given by intravenous infusions for 28 days. The other 22 cases were treated without any form of antiviral therapy as control. After the therapy, all patients were treated by basic surporting therapy. All patients were followed-up for 6 months. The HBV markers, quantification of HBV DNA,serochemical data were measured at baseline,during therapy and at the end of follow-up. Results At the end of fosearnet sodium treatment,the level of serum HBV DNA in antiviral group desereased more obviously than in the contorl gorup （P〈0.05）. Clinical symptoms were improved in two groups,meanwhile alanine aminotransferase and total serum bilirubin decreased. The efficiency of HBV DNA decreased of more than two log was 42.9% and 30.0%,respectively in foscarnet sodium treatment groups and in control group at the end of follow-up. Conclusion Fosearnet sodium therapy can inhibit HBV replication in treating chronic hepatitis B of severe type. It can rapidly decrease the level of serum HBV DNA levels.